Last reviewed · How we verify
Doxercalciferol administration
At a glance
| Generic name | Doxercalciferol administration |
|---|---|
| Sponsor | Southeast Renal Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis (PHASE3)
- Vitamin D and Carboxy PTH Fragments in Coronary Calcification (PHASE4)
- Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (PHASE2)
- Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis (PHASE4)
- Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease (NA)
- How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis (PHASE4)
- A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection (PHASE4)
- A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |